Aelis Farma’s AEF0117 THC Interaction Trial Withdrawn: What Investors Should Know

WHY IT MATTERS: Patients and clinicians hoping for a targeted pharmacological tool to manage THC overconsumption or cannabis use disorder may face longer timelines before any such option becomes available. CLINICAL OVERVIEW: AEF0117 is a first-in-class CB1 receptor signaling inhibitor developed by Aelis Farma, designed to selectively block certain downstream effects of THC without fully antagonizing the receptor, representing a novel pharmacological approach to cannabis use disorder and THC-related adverse effects. The withdrawal of a THC interaction trial is a meaningful setback because interaction studies are critical for characterizing how AEF0117 behaves in the presence of active THC, which is the precise clinical scenario the drug is meant to address.

Read More

Study Finds Veterans With SUD Used Cannabis to Alleviate Pain, Anxiety, and Improve Poor …

WHY IT MATTERS: If you are a veteran managing pain, anxiety, or sleep issues alongside a substance use disorder, this research supports having an honest conversation with your care team about whether supervised cannabis use could be a safer part of your recovery plan. CLINICAL OVERVIEW: New research examining veterans with substance use disorders found that many turned to cannabis to manage pain, anxiety, and sleep disturbances during their treatment for non-cannabis-related SUD. This aligns with what we see clinically, where patients often use cannabis as an adjunct or alternative to more harmful substances, particularly opioids and benzodiazepines.

Read More